US equities |
TSLA $392.26 ▲+5.39% MU $902.57 ▲+2.85% NVDA $216.34 ▲+2.55% SPCX $147.38 ▼-0.07% META $631.52 ▼-1.73% AAPL $344.57 ▼-0.91% SNDK $1,255.04 ▲+1.37% INTC $90.71 ▲+4.31%
FinancialContent

Lucid Diagnostics Inc. - Common Stock (NQ:LUCD)

0.5122 +0.1012 (+24.62%)
Delayed Quote Updated: 3:51 PM EDT, Oct 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Lucid Diagnostics Inc. - Common Stock

< Previous 1 2 3 4 Next >
Top US Stock Gainers and Losers in Today's Session ↗
Via Chartmill
Most Active US Stocks: Oct. 23, 2026 Volume Leaders ↗
Via Chartmill
Today's U.S. Session Top Movers: Small-Cap Gainers and Losers ↗
Via Chartmill
Gap-Up and Gap-Down Stocks: October 23, 2026 Session ↗
Via Chartmill
Premarket Movers: October 23, 2026 US Session ↗
Via Chartmill
News headline image
Earnings Scheduled For November 12, 2025 ↗
 
Via Benzinga
Postmarket Movers: After-Hours Gainers and Decliners ↗
Via Chartmill
After-Hours US Movers: STAK, NCPL, CRMT Gain; NVEC, HKPD, LHSW Fall ↗
Via Chartmill
What's going on in today's after hours session ↗
Via Chartmill
Which stocks are experiencing notable movement on Thursday? ↗
Via Chartmill
News headline image
3 Key Reasons to Buy This Huge Turnaround Story That's Gaining Traction ↗
After shedding roughly 75% of its value during the past three years, it might not take much improvement for Stellantis' stock price to pop. 
Via The Motley Fool
Topics Electric Vehicles
News headline image
Lucid Diagnostics (LUCD) Q2 2026 Earnings Call Transcript ↗
Revenue jumped 17% as company shifts focus to higher-reimbursement opportunities. 
Via The Motley Fool
Topics Earnings
News headline image
Lucid Diagnostics Eyes Medicare Catalyst for EsoGuard Growth ↗
Lucid Diagnostics (NASDAQ:LUCD) is positioning its EsoGuard test as a non-invasive tool to identify Barrett’s Esophagus, a precancerous condition associated with esophageal cancer, while it awaits a... 
Via MarketBeat
Topics Death
News headline image
Lucid Diagnostics Q2 Earnings Call Highlights ↗
Lucid Diagnostics (NASDAQ:LUCD) reported second-quarter revenue of $1.5 million on 2,770 EsoGuard tests, as the company continued to target quarterly test volume of roughly 2,500 to 3,000 tests while... 
Via MarketBeat
Topics Earnings
News headline image
Lucid Diagnostics Q2 2026 Earnings Call: Complete Transcript ↗
Lucid Diagnostics (NASDAQ:LUCD) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This content is powered by Benzinga APIs. For... 
Via Benzinga
Topics Earnings
News headline image
PAVmed (PAVM) Q4 2025 Earnings Transcript ↗
PAVmed (PAVM) Q4 2025 Earnings Transcript 
Via The Motley Fool
News headline image
LUCD Q1 2026 Earnings Transcript ↗
LUCD Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Lucid Diagnostics Q1 Earnings Call Highlights ↗
Lucid Diagnostics (NASDAQ:LUCD) reported first-quarter 2026 EsoGuard test volume above its pre-Medicare target range, while management said it continues to await a Medicare local coverage determination... 
Via MarketBeat
Topics Earnings
News headline image
Lucid Diagnostics (LUCD) Earnings Transcript ↗
Lucid Diagnostics (LUCD) Earnings Transcript 
Via The Motley Fool
News headline image
PAVM Stock Shot Up Over 250% Today – What’s The Deal With The Department of Veterans Affairs? ↗
The company’s subsidiary, Lucid Diagnostics, secured a contract from the U.S. Department of Veterans Affairs to provide its EsoGuard Esophageal DNA Test for the detection of esophageal precancer. 
Via Stocktwits
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
LUCID DIAGNOSTICS INC (NASDAQ:LUCD) Reports Q2 2025 Earnings In Line with Estimates, Narrower Loss Than Expected ↗
Lucid Diagnostics (LUCD) Q2 2025 results: Revenue $1.16M, EPS -$0.10, beating estimates. Processed 2,756 EsoGuard tests, maintains $30M+ cash. Stock up 2.26% pre-market. 
Via Chartmill
News headline image
LUCD Reports Results ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
SAIC, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 13, 2025 ↗
 
Via Benzinga
News headline image
Why Blueprint Medicines Shares Are Trading Higher By 27%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
< Previous 1 2 3 4 Next >